tbuckley/cabot-search huggingface dataset:
195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis
Authors: C.F. Singer, D. Egle, R. Greil, E. Petru, L. Ohler, M. Balic, C. Tinchon, G. Pfeiler, M. Marhold, C. Brunner, K. Haider, A. Galid, U. Pluschnig, F. Haslbauer, M. Hubalek, A. Redl, J. Flatschacher, S. Uthman, B. Mraz, R. Bartsch
Journal: Annals of Oncology (2022)
SETTING UP A REGIONAL EXPERT PANEL FOR COMPLEX COLORECTAL POLYPS
Authors: L.W. Zwager, B.A. Bastiaansen, E. Dekker, P. Fockens
Journal: Endoscopy (2022)

Aims Advanced endoscopic resection techniques for complex colorectal polyps have evolved significantly over the past decade, leading to a management shift from surgical to endoscopic resection as the preferred treatment. However in practice, interhospital consultation and access to the required expertise for appropriate referral management remain challenging and under-used. In order to support regional care for patients with complex colorectal polyps, facilitate peer consultations and lower thresholds for referrals, an expert panel consultation platform was initiated in the northwestern region of the Netherlands.
ANTEGRADE PANCREATOSCOPY VIA PANCREATO-GASTROSTOMY: GUIDEWIRE FRAGMENT EXTRACTION AND TOTAL STENOSIS CONFIRMATION
Authors: D. Luna-Rodriguez, I. Fajardo, C. Loras, A. Garcia-Sumalla, J.B Gornals
Journal: Endoscopy (2022)

A 52yo man with chronic pancreatitis of unknown origin, with neck stenosis and pancreatic ductal lithiasis. After failure of transpapillary cannulation, a Rendezvous technique is realized. After several tries without success, fragmentation of intrapancreatic guidewire occurs. A transmural drainage (USE-guided pancreatic-gastrostomy) with 2 plastic stents is realized. Then,an antegrade pancreatoscopy via pancreato-gastrostomy (SpyGlass-DSII) is made. Main pancreatic duct dilatation, with no lithiasis but with several parenchymatous calcificacions that cause total ductal stenosis. Guidewire fragment identification and retrieval with spy-basket.Another Rendezvous for a transpapillary conversion is made, without success. A third coaxial plastic stent is placed, optimizing the transmural pancreatic drainage
CURATIVE ESD OF A LARGE GASTRIC MALT-LYMPHOMA
Authors: L. Rivero-Sánchez, E. Van Den Neste, H. Dano, P.H. Deprez
Journal: Endoscopy (2022)

A 65-year-old male was diagnosed with Helicobacter pylori-negative gastric mucosal-associated lymphoid tissue (MALT)-lymphoma, measuring 46mm with a protruding shape and subepithelial appearance in the corpus-fundus junction. EUS showed mucosal involvement without parietal extension. After treatment with antibiotics and Rituximab, no endoscopic/histological response was observed at 12-month follow-up. After treatment option discussions in a multidisciplinary meeting, an en-bloc endoscopic submucosal dissection (ESD) was performed without complications. Histopathology revealed free deep and lateral margins. Follow-up at 6 and 12 months showed no endoscopic/histological recurrence. This report provides further support of ESD as a minimally invasive second-line treatment of MALT-lymphoma in selected patients.
EUS, CH-EUS, FNA AND FNB OF DEGENERATED IPMN
Authors: A. Mauriello, F. Castellano, M. Sacco, F. Fimiano, M. Gesualdo, G.M. Benazzo, C.G. De Angelis
Journal: Endoscopy (2022)

This video presents the case of 57-year-old woman with onset of epigastric pain with posterior irradiation, dyspepsia, asthenia and recent weight loss; blood test detected high serum level of Carbohydrate antigen 19-9 (5148 U/ml) without alteration of serum amylase and lipase; on the other hand, abdominal CT showed multiple pancreatic cysts with pancreatic atrophy and no clear masses. EUS-FNA and EUS-FNB were performed obtaining the diagnosis of adenocarcinoma cells in a context of necrotic tissue. The final diagnosis was IPMN degenerated with a vascular infiltration. Due to vascular infiltration, a chemotherapy regimen was started.
EVALUATION OF THE EFFECT OF GASTRIC TARGETED BIOPSY SAMPLING WITH I-SCAN OE TECHNOLOGY ON THE DIAGNOSTIC YIELD OF THE CLO TEST OF H. PYLORI INFECTION
Authors: H. Dawod
Journal: Endoscopy (2022)

Corrected by: Correction: EVALUATION OF THE EFFECT OF GASTRIC TARGETED BIOPSY SAMPLING WITH I-SCAN OE TECHNOLOGY ON THE DIAGNOSTIC YIELD OF THE CLO TEST OF H. PYLORI INFECTIONEndoscopy 2022; 54(S 01): C6-C6DOI: 10.1055/a-1844-1534
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for<i>BRAF</i>V600–Mutant Unresectable or Metastatic Melanoma
Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul D. Nathan, Piotr Rutkowski, Oleg Leonov, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean Jacques Grob, Nicolas Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steven Green, Tomas Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf
Journal: Journal of Clinical Oncology (2022)

Preclinical data suggest the combination of an anti-programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600-mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, an anti-programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600-mutant unresectable or metastatic melanoma.Patients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily or placebo-DabTram. Participants were age ≥ 18 years with unresectable or metastatic BRAF V600-mutant melanoma. The primary end point was investigator-assessed progression-free survival. Overall survival was a key secondary end point (ClinicalTrials.gov identifier: NCT02967692).At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = .042 [one-sided; nonsignificant]). The objective response rates were 69% (183 of 267 patients) versus 64% (170 of 265 patients), respectively. Grade ≥ 3 treatment-related adverse events occurred in 55% (146 of 267) of patients in the sparta-DabTram arm and 33% (88 of 264) in the placebo-DabTram arm.The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.
INFORMED CONSENT IN ENDOSCOPY: READ, UNDERSTOOD OR MERELY SIGNED
Authors: A.C. Carvalho, R. Cardoso, F. Pires, S. Ventura, C. Rodrigues, Â. Domingues, J. Pinho, D. Martins, P. Sousa, R. Araújo, E. Cancela, A. Castanheira, P. Ministro, M. Vieira, A. Silva
Journal: Endoscopy (2022)

Aims While informed consent is a requirement for all invasive procedures such as those in gastrointestinal endoscopy, its standardization is a challenge. Recently, our national digestive endoscopy society developed proposals for informed consent forms and information leaflets for esophagogastroduodenoscopy and colonoscopy.
BILIARY DRAINAGE IN PATIENTS WITH CHOLANGIOCARCINOMA: A COMPARISON BETWEEN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY AND PERCUTANEOUS TRANSHEPATIC APPROACHES
Authors: C. Flaksbaum Moll, J.M. Vera Intriago, M.F. Shinin Merchan, E. Guimarães Hourneaux de Moura, E. Silvino do Monte Junior, I. Mendonça Proença, I. Braga Ribeiro, W. Marques Bernardo, D. Turiani Hourneaux de Moura
Journal: Endoscopy (2022)

Aims The aim of this systematic review and meta-analysis is to elucidate which is the optimal approach for biliary drainage in patients with cholangiocarcinoma.
Landscape of DILI-related adverse drug reaction in China Mainland
Authors: Jiabo Wang, Haibo Song, Feilin Ge, Peng Xiong, Jing Jing, Tingting He, Yuming Guo, Zhuo Shi, Chao Zhou, Zixin Han, Yanzhong Han, Ming Niu, Zhaofang Bai, Guangbin Luo, Chuanyong Shen, Xiaohe Xiao
Journal: Acta Pharmaceutica Sinica B (2022)

Drug-induced liver injury (DILI) is a type of bizarre adverse drug reaction (ADR) damaging liver (L-ADR) which may lead to substantial hospitalizations and mortality. Due to the general low incidence, detection of L-ADR remains an unsolved public health challenge. Therefore, we used the data of 6.673 million of ADR reports from January 1st, 2012 to December 31st, 2016 in China National ADR Monitoring System to establish a new database of L-ADR reports for future investigation. Results showed that totally 114,357 ADR reports were retrieved by keywords searching of liver-related injuries from the original heterogeneous system. By cleaning and standardizing the data fields by the dictionary of synonyms and English translation, we resulted 94,593 ADR records reported to liver injury and then created a new database ready for computer mining. The reporting status of L-ADR showed a persistent 1.62-fold change over the past five years. The national population-adjusted reporting numbers of L-ADR manifested an upward trend with age increasing and more evident in men. The annual reporting rate of L-ADR in age group over 80 years old strikingly exceeded the annual DILI incidence rate in general population, despite known underreporting situation in spontaneous ADR reporting system. The percentage of herbal and traditional medicines (H/TM) L-ADR reports in the whole number was 4.5%, while 80.60% of the H/TM reports were new findings. There was great geographical disparity of reported agents, i.e. more cardiovascular and antineoplastic agents were reported in higher socio-demographic index (SDI) regions and more antimicrobials, especially antitubercular agents, were reported in lower SDI regions. In conclusion, this study presented a large-scale, unbiased, unified, and computer-minable L-ADR database for further investigation. Age-, sex- and SDI-related risks of L-ADR incidence warrant to emphasize the precise pharmacovigilance policies within China or other regions in the world.
196P Final analysis of PUFFIN: A phase III, randomised double-blind, placebo (Pla)-controlled study of pertuzumab, trastuzumab and docetaxel (PHD) for Chinese patients (pts) with previously untreated HER2-positive locally recurrent or metastatic breast cancer (LR/MBC)
Authors: B. Xu, W. Li, Q. Zhang, Q. Li, X. Wang, H. Li, T. Sun, Y. Yin, H. Zheng, J. Feng, H. Zhu, A. Siddiqui, H.N. Macharia, A. Knott
Journal: Annals of Oncology (2022)
Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with a new dengue rapid diagnostic test: a retrospective analysis of phase 3 efficacy trials
Authors: Stephen J Savarino, Matthew Bonaparte, Hao Wang, Gustavo H Dayan, Remi Forrat, Ming Zhu, Shekema Hodge, Yasemin Ataman-Önal, Carlos A DiazGranados
Journal: The Lancet Microbe (2022)

A dengue pre-vaccination test that is convenient, highly specific, and highly sensitive is still needed. The OnSite Dengue IgG rapid diagnostic test (RDT) is a new rapid diagnostic test specifically designed for pre-vaccination screening. We aimed to retrospectively assess the efficacy of a tetravalent dengue vaccine (CYD-TDV) in participants determined to be dengue seropositive by the OnSite IgG RDT and to evaluate assay performances.This was a complementary study using pre-vaccination samples from two CYD-TDV efficacy trials done in five countries in the Asia-Pacific region (NCT01373281) and five countries in Latin America (NCT01374516). Baseline dengue serostatus was determined by the OnSite IgG RDT on samples from the immunogenicity subsets of the two trials. In participants who were test positive, we calculated CYD-TDV vaccine efficacy against symptomatic virologically confirmed dengue (VCD) over 25 months, and against hospitalisation with VCD over 72 months of follow-up after the first vaccination. We used a reference algorithm to determine the reference dengue serostatus for each sample, and sensitivity and specificity of the OnSite IgG RDT were calculated. Analyses were done on the whole population (aged 2-16 years), and on those aged 6 years or older and those aged 9 years or older.Of 3983 participants in the immunogenicity subsets of the efficacy trials CYD14 and CYD15, 3962 had complete dengue reference test results enabling baseline serostatus classification and 3833 had sufficient serum samples remaining for evaluation with the OnSite IgG RDT. Of the samples tested, 2486 (64·9%) of 3833 were OnSite IgG RDT-positive. In participants aged 2-16 years who were OnSite IgG RDT-positive, vaccine efficacy was 84·1% (95% CI 71·6-91·1) against symptomatic VCD, and 69·2% (38·8-84·5) against hospitalisation with VCD, with similar findings in those aged 6 years or older and those aged 9 years or older. The OnSite IgG RDT showed very high sensitivity (91·1%, 89·9-92·1) and high specificity (92·8%, 91·2-94·2) in participants aged 2-16 years, with significantly higher specificity in those aged 9 years or older (96·6%, 94·9-97·8).The OnSite IgG RDT should provide a valuable tool for screening for previous dengue infection at the point of vaccination. In individuals who were OnSite IgG RDT-positive, the vaccine efficacy of CYD-TDV was high across all three age groups.Sanofi Pasteur.
168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: Findings from the phase III ASCENT study
Authors: S.A. Hurvitz, A. Bardia, K. Punie, K. Kalinsky, J. Cortés, J. O'Shaughnessy, L.A. Carey, H.S. Rugo, O.K. Yoon, Y. Pan, R.J. Delaney, S. Hofsess, P. Hodgkins, S-C. Phan, V. Dieras
Journal: Annals of Oncology (2022)
167MO Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial
Authors: T. De La Motte Rouge, J-S. Frenel, A-C. Hardy-Bessard, T. Bachelot, B. Pistilli, S. Delaloge, L. Deiana, F. Del Piano, D. Genet, M. Gardner, E. Legouffe, C.B. Levache, H. Orfeuvre, C. Valmar, L. Venat, A. Zannetti, R. Le Scodan, F. Dalenc, D. Berger, F.C. Bidard
Journal: Annals of Oncology (2022)
LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)
Authors: P. Neven, P.A. Fasching, S. Chia, G. Jerusalem, M. De Laurentiis, S.-A. Im, K. Petrakova, G.V. Bianchi, M. Martin Jimenez, A. Nusch, G.S. Sonke, L. de la Cruz Merino, J.T. Beck, J.P. Zarate, Y. Wang, A. Chakravartty, C. Wang, D. Slamon
Journal: Annals of Oncology (2022)
RATIONALISING THE USE OF SPECIMEN POTS FOLLOWING COLORECTAL POLYPECTOMY– A SMALL STEP TOWARDS GREENER ENDOSCOPY
Authors: K.K. Yong, Y. He, H.C. Cheung, R. Sriskandarajah, W. Jenkins, S. Beg
Journal: Endoscopy (2022)

Aims Endoscopy departments are responsible for the third highest rate of hospital related greenhouse gas (GHG) emissions. In this study, we aim to determine whether combining multiple diminutive colorectal polyps within a single specimen pot can reduce waste without causing deleterious clinical impact.
Endoscopic ultrasound-guided intra-afferent loop entero-enterostomy using a forward-viewing echoendoscope and insertion of a metal stent
Authors: Yuki Kawasaki, Susumu Hijioka, Kosuke Maehara, Kiichi Tamada, Takuji Okusaka, Yutaka Saito
Journal: Endoscopy (2022)

Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is a treatment option for afferent loop syndrome [1], with the use of various stents having been reported [2] [3] [4] [5]. However, depending on the site of the stenosis of the afferent loop, fistulization from the stomach can be difficult. We introduce an entero-enterostomy technique using a forward-viewing echoendoscope and metal stent for the treatment of afferent loop syndrome.
The lived experience of psychosis: a bottom‐up review co‐written by experts by experience and academics
Authors: Paolo Fusar‐Poli, Andrés Estradé, Giovanni Stanghellini, Jemma Venables, Juliana Onwumere, Guilherme Messas, Lorenzo Gilardi, Barnaby Nelson, Vikram Patel, Ilaria Bonoldi, Massimiliano Aragona, Ana Cabrera, Joseba Rico, Arif Hoque, Jummy Otaiku, Nicholas Hunter, Melissa G. Tamelini, Luca F. Maschião, Mariana Cardoso Puchivailo, Valter L. Piedade, Péter Kéri, Lily Kpodo, Charlene Sunkel, Jianan Bao, David Shiers, Elizabeth Kuipers, Celso Arango, Mario Maj
Journal: World Psychiatry (2022)

Psychosis is the most ineffable experience of mental disorder. We provide here the first co-written bottom-up review of the lived experience of psychosis, whereby experts by experience primarily selected the subjective themes, that were subsequently enriched by phenomenologically-informed perspectives. First-person accounts within and outside the medical field were screened and discussed in collaborative workshops involving numerous individuals with lived experience of psychosis as well as family members and carers, representing a global network of organizations. The material was complemented by semantic analyses and shared across all collaborators in a cloud-based system. The early phases of psychosis (i.e., premorbid and prodromal stages) were found to be characterized by core existential themes including loss of common sense, perplexity and lack of immersion in the world with compromised vital contact with reality, heightened salience and a feeling that something important is about to happen, perturbation of the sense of self, and need to hide the tumultuous inner experiences. The first episode stage was found to be denoted by some transitory relief associated with the onset of delusions, intense self-referentiality and permeated self-world boundaries, tumultuous internal noise, and dissolution of the sense of self with social withdrawal. Core lived experiences of the later stages (i.e., relapsing and chronic) involved grieving personal losses, feeling split, and struggling to accept the constant inner chaos, the new self, the diagnosis and an uncertain future. The experience of receiving psychiatric treatments, such as inpatient and outpatient care, social interventions, psychological treatments and medications, included both positive and negative aspects, and was determined by the hope of achieving recovery, understood as an enduring journey of reconstructing the sense of personhood and re-establishing the lost bonds with others towards meaningful goals. These findings can inform clinical practice, research and education. Psychosis is one of the most painful and upsetting existential experiences, so dizzyingly alien to our usual patterns of life and so unspeakably enigmatic and human.
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response
Authors: Timothy A. Yap, Justin F. Gainor, Margaret K. Callahan, Gerald S. Falchook, Russell K. Pachynski, Patricia LoRusso, Shivaani Kummar, Geoffrey T. Gibney, Howard A. Burris, Scott S. Tykodi, Osama E. Rahma, Tanguy Y. Seiwert, Kyriakos P. Papadopoulos, Mariela Blum Murphy, Haeseong Park, Amanda Hanson, Yasmin Hashambhoy-Ramsay, Lara McGrath, Ellen Hooper, Xiaoying Xiao, Heather Cohen, Martin Fan, Daniel Felitsky, Courtney Hart, Rachel McComb, Karen Brown, Ali Sepahi, Judith Jimenez, Weidong Zhang, Johan Baeck, Haley Laken, Richard Murray, Elizabeth Trehu, Christopher J. Harvey
Journal: Clinical Cancer Research (2022)

The first-in-human phase I/II ICONIC trial evaluated an investigational inducible costimulator (ICOS) agonist, vopratelimab, alone and in combination with nivolumab in patients with advanced solid tumors.In phase I, patients were treated with escalating doses of intravenous vopratelimab alone or with nivolumab. Primary objectives were safety, tolerability, MTD, and recommended phase II dose (RP2D). Phase II enriched for ICOS-positive (ICOS+) tumors; patients were treated with vopratelimab at the monotherapy RP2D alone or with nivolumab. Pharmacokinetics, pharmacodynamics, and predictive biomarkers of response to vopratelimab were assessed.ICONIC enrolled 201 patients. Vopratelimab alone and with nivolumab was well tolerated; phase I established 0.3 mg/kg every 3 weeks as the vopratelimab RP2D. Vopratelimab resulted in modest objective response rates of 1.4% and with nivolumab of 2.3%. The prospective selection for ICOS+ tumors did not enrich for responses. A vopratelimab-specific peripheral blood pharmacodynamic biomarker, ICOS-high (ICOS-hi) CD4 T cells, was identified in a subset of patients who demonstrated greater clinical benefit versus those with no emergence of these cells [overall survival (OS), P = 0.0025]. A potential genomic predictive biomarker of ICOS-hi CD4 T-cell emergence was identified that demonstrated improvement in clinical outcomes, including OS (P = 0.0062).Vopratelimab demonstrated a favorable safety profile alone and in combination with nivolumab. Efficacy was observed only in a subset of patients with a vopratelimab-specific pharmacodynamic biomarker. A potential predictive biomarker of response was identified, which is being prospectively evaluated in a randomized phase II non-small cell lung cancer trial. See related commentary by Lee and Fong, p. 3633.
COLORECTAL CANCER DIAGNOSTIC CIRCUIT PERFORMANCE AND ITS IMPACT BY THE COVID19 PANDEMIC AT THE GIRONA REFERRAL HOSPITAL
Authors: M. Albert, E. Guarner, G. Espin, M. Hombrados, D. Busquets, L. Pardo, L. Torrealba, B. Oliveras, C. Huertas, C. Lopez
Journal: Endoscopy (2022)

Aims Colorectal Cancer (CRC) Diagnostic Circuit (CDR) is designed to provide comprehensive care for suspected CRC. The suspension of endoscopic and healthcare activity due to COVID-19 could have affected the CDR performance.
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study
Authors: Timo Deutschbein, Giuseppe Reimondo, Guido Di Dalmazi, Irina Bancos, Jekaterina Patrova, Dimitra Argyro Vassiliadi, Anja Barač Nekić, Miguel Debono, Pina Lardo, Filippo Ceccato, Luigi Petramala, Alessandro Prete, Iacopo Chiodini, Miomira Ivović, Kalliopi Pazaitou-Panayiotou, Krystallenia I Alexandraki, Felicia Alexandra Hanzu, Paola Loli, Serkan Yener, Katharina Langton, Ariadni Spyroglou, Tomaz Kocjan, Sabina Zacharieva, Nuria Valdés, Urszula Ambroziak, Mari Suzuki, Mario Detomas, Soraya Puglisi, Lorenzo Tucci, Danae Anastasia Delivanis, Dimitris Margaritopoulos, Tina Dusek, Roberta Maggio, Carla Scaroni, Antonio Concistrè, Cristina Lucia Ronchi, Barbara Altieri, Cristina Mosconi, Aristidis Diamantopoulos, Nicole Marie Iñiguez-Ariza, Valentina Vicennati, Anna Pia, Matthias Kroiss, Gregory Kaltsas, Alexandra Chrisoulidou, Ljiljana V Marina, Valentina Morelli, Wiebke Arlt, Claudio Letizia, Marco Boscaro, Antonio Stigliano, Darko Kastelan, Stylianos Tsagarakis, Shobana Athimulam, Uberto Pagotto, Uwe Maeder, Henrik Falhammar, John Newell-Price, Massimo Terzolo, Martin Fassnacht
Journal: The Lancet Diabetes & Endocrinology (2022)
ENDOSCOPIC ULTRASOUND (EUS) DEPENDENT DECISION TO PERFORM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY (ERCP) IN EARLY BILIARY PANCREATITIS WITHOUT CHOLESTASIS ON CONVENTIONAL IMAGING – FINAL RESULTS
Authors: S. Bota, M. Razpotnik, G. Essler, C. Urak, J. Weber-Eibel, M. Peck-Radosavljevic
Journal: Endoscopy (2022)

Aims To assess the outcome of acute biliary pancreatitis (ABP) using EUS for deciding to perform an ERCP.